Date:	10/27/2022			
Your Name:	Arun Sanyal			
Manuscript Title:	Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: a post hoc analysis o the FALCON 1 trial			
Manuscript Number (if known):	JHEPR-D-22-00117			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			tities with whom you have this or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ None	Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None		
3	Royalties or licenses	⊠ None	See attached	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None See attached	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	None See attached	Stock owner	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
13	Other financial or non-financial interests	□ None		
Plea	Please place an "X" next to the following statement to indicate your agreement:			

ARUN J SANYAL M.D. CONFLICT OF INTEREST DISCLOSURE TABLE JULY 2022 (based on incomes over last 24 months)

A: No interest

B: <\$ 5000

C: \$ 5001-10,000

- D: \$10,001-\$50,000
- E: \$ 50,001-100,000

F: >\$ 100,000

Company	Stock	Employment	Speaker	Consulting	Research	Travel	Intellectual	Royalties
EVILAL ENZ	В			advisor	grants	grants	property	
EXHALENZ				D				
GENFIT	D			B	1			
GILEAD				В	F			
ELSEVIER								В
ECHOSENSE-					A^{\wedge}			
SANDHILL								
MALINCKRODT				D	Е			
INTERCEPT				A*				
Pfizer				В				
SALIX				В				
UPTODATE								С
BOEHRINGER				В	Е			
INGELHIEM								
NOVARTIS				С	Е			
BRISTOL				В	E			
Myers								
SQUIBB								
MERCK				С	Е			
SEQUANA				A^^				
HEMOSHEAR	С			В				
LILLY				С	Е			
NOVO NORDISK				D	Е			
FRACTYL				A*	Е			
DURECT	С							
INDALO	С							

The second se		D			
TERNS		D			
ALBIREO		В			
JANNSEN		В			
NORTHSEA	С				
POXEL		В			
TIZIANA	С				
89 BIO		В			
SIEMENS		В	A^{\wedge}		
ASTRA ZENECA		C**			
NGM BIO		В			
AMGEN		В			
REGENERON		С			
GENENTECH		В			
ALNYLAM		В			
ROCHE		В			
RIVUS	С				
MADRIGAL		В	Е		
INVENTIVA		В	Е		
COVANCE		В			
PROSCIENTO		В			
HISTOINDEX		D			
PATH AI		В			

- ^ ongoing research collaboration without directs funds to Dr. Sanyal
- ^^ member of DSMB for a study
- ^^^ provided drug for NIAAA trial of Imm124 for alcoholic hepatitis. I have received no funds from Immuron
- * I am a consultant but have not received personal remuneration
- ** AZ provided remuneration to VCU for my effort as a consultant. This contract was discontinued 1 year ago.
- Research grants represent the site budgets for VCU clinical trials involving these companies and do not support me directly.

Date:	Click or tap to enter a date.
Your Name:	Elizabeth Brown
Manuscript Title:	Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: a post hoc analysis of the FALCON 1 trial
Manuscript Number (if known):	JHEPR-D-22-00117

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
		Time frame: Since the initial planning of the work					
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not	None Time frame: past 36 month None	Click the tab key to add additional rows.				
	indicated in item #1 above).						
3	Royalties or licenses	None					

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None □ □ □ □ □ □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	⊠ None □ □ □ □ □ □ □ □			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None			
13	Other financial or non-financial interests	D None Bristol Myers Squibb	Employee at the time of the study		
	Please place an "X" next to the following statement to indicate your agreement:				
	I certify that I have	answered every question and have not altered the wo	rding of any of the questions on this form.		

Date:	9/29/2022
our Name:Edgar D. Charles	
Manuscript Title:	Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: a post hoc analysis of the FALCON 1 trial
Manuscript Number (if known):	JHEPR-D-22-00117

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Image: None Bristol Myers Squibb Image: Bristol Myers Squibb Image: Descent of the second seco	Employment Click the tab key to add additional rows.
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None □ □ □ □ □ □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None Bristol Myers Squibb	stock
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	⊠ None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	Click or tap to enter a date.	
Your Name:	Giovanni Cizza	
Manuscript Title:	Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: a post hoc analysis of the FALCON 1 trial	
Manuscript Number (if known):	JHEPR-D-22-00117	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ □ <t< th=""><th>Click the tab key to add additional rows.</th></t<>	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None □ □ □ □ □ □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None □ □ □ □ □ □ □ □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None □ □ □ □ □ □	
13	Other financial or non-financial interests	D None Bristol Myers Squibb	Employee at the time of the study
Please place an "X" next to the following statement to indicate your agreement:			
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: Click or tap to enter a date.	
Your Name:	Shuyan Du
Manuscript Title:	Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: a post hoc analysis of the FALCON 1 trial
Manuscript Number (if known):	JHEPR-D-22-00117

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☑ None ☑ □ <	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None □ □ □ □ □ □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	Image: None	
		Bristol Myers Squibb	Stock owner
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None Bristol Myers Squibb	Full time employee
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	Click or tap to enter a date.	
Your Name:	Richard Ehman	
Manuscript Title:	Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: a post hoc analysis of the FALCON 1 trial	
Manuscript Number (if known):	JHEPR-D-22-00117	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	□ □ □ □	Click the tab key to add additional rows. S
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
		Bristol Myers Squibb	Stock owner
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None □ □ □ □ □ □	
13	Other financial or non-financial interests	None Along with Mayo Clinic, intellectual property rights and a financial interest related to MR elastography technology	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	10/16/2022	
Your Name:	Morten Karsdal	
Manuscript Title:	Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: a post hoc analysis of the FALCON 1 trial	
Manuscript Number (if known):	JHEPR-D-22-00117	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Image: Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	 None 	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None	Stock options in Nordic Bioscience
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	⊠ None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	10/1/2022
Your Name:	Diana Julie Leeming
Manuscript Title:	Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: a post hoc analysis of the FALCON 1 trial
Manuscript Number (if known):	JHEPR-D-22-00117

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		of the work
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☑ None ☑ Time frame: past 36 month ☑ None	Click the tab key to add additional rows.
2	contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None □ □ □ □ □ □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None Nordic Bioscience	Diana Julie Leeming is a stock owner
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	None Nordic Bioscience	Full time employee
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	10/17/2022	
Your Name:	Rohit Loomba	
Manuscript Title:	Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: a post hoc analysis of the FALCON 1 trial	
Manuscript Number (if known):	JHEPR-D-22-00117	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Image: Second se	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None	
3	Royalties or licenses	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees		
		RL serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics.	
5	Payment or honoraria for lectures, presentations, speakers	□ None	
	bureaus, manuscript writing or educational events		
6	Payment for expert testimony	□ None	
7	Support for attending	D None	
	meetings and/or travel		
8	Patents planned,	None	
	issued or pending		
9	Participation on a Data Safety Monitoring	│ □ None	
	Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	other board, society, committee or advocacy group, paid or unpaid					
11	Stock or stock options	□ None				
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None				
13	Other financial or non-financial interests	None Co-founder of LipoNexus Inc.				
Plea	Please place an "X" next to the following statement to indicate your agreement:					

Date:	Click or tap to enter a date.
Your Name:	Anne Minnich
Manuscript Title:	Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: a post hoc analysis of the FALCON 1 trial
Manuscript Number (if known):	JHEPR-D-22-00117

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)					
		Time frame: Since the initial planning of the work						
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	□ □ □ □	Click the tab key to add additional rows. S					
3	Royalties or licenses	None						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	⊠ None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
13	Other financial or non-financial interests	None Bristol Myers Squibb	Consultant	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

ARUN J SANYAL M.D. CONFLICT OF INTEREST DISCLOSURE TABLE JULY 2022 (based on incomes over last 24 months)

A: No interest

B: <\$ 5000

C: \$ 5001-10,000

- D: \$10,001-\$50,000
- E: \$50,001-100,000

F: >\$ 100,000

Company	Stock	Employment	Speaker	Consulting	Research	Travel	Intellectual	Royalties
				advisor	grants	grants	property	
EXHALENZ	В	A	А	A	A	A	A	A
GENFIT	D	A	Α	В	Α	A	Α	А
GILEAD	А	А	А	В	F	А	А	А
Elsevier	А	А	А	А	А	А	А	В
ECHOSENSE-	А	А	А	А	A^{\wedge}	А	А	А
SANDHILL								
MALINCKRODT	А	А	А	D	E	А	А	А
INTERCEPT	А	А	А	A*	А	А	А	А
Pfizer	А	А	А	В	А	А	А	А
SALIX	А	А	А	В	А	А	А	А
UPTODATE	А	А	А	А	А	А	А	С
BOEHRINGER	А	А	А	В	Е	А	А	А
INGELHIEM								
NOVARTIS	А	А	А	С	E	А	А	А
BRISTOL	А	Α	А	В	E	А	А	А
Myers								
SQUIBB								
MERCK	А	А	А	С	E	А	А	А
SEQUANA	А	А	А	A^^	А	А	А	А
HEMOSHEAR	С	А	А	В	А	А	А	А
LILLY	А	А	А	С	Е	А	А	А
NOVO NORDISK	А	A	А	D	Е	А	А	А
FRACTYL	А	А	А	A*	Е	А	А	А
DURECT	С	А	А	А	А	А	А	А
INDALO	С	A	А	А	А	А	А	А

				_				
TERNS	A	A	A	D	A	A	A	A
ALBIREO	А	А	А	В	А	А	А	А
JANNSEN	А	А	А	В	А	А	А	А
NORTHSEA	С	А	А	А	А	А	А	А
POXEL	А	А	А	В	А	А	А	А
TIZIANA	С	А	А	А	А	А	А	А
89 BIO	А	А	А	В	А	А	А	А
SIEMENS	А	А	А	В	A^{\wedge}	А	А	А
ASTRA ZENECA	А	А	А	C**	А	А	А	А
NGM BIO	А	А	А	В	А	А	А	А
AMGEN	А	А	А	В	А	А	А	А
REGENERON	А	А	А	С	А	А	А	А
GENENTECH	А	А	А	В	А	А	А	А
ALNYLAM	А	А	А	В	А	А	А	А
ROCHE	А	А	А	В	А	А	А	А
RIVUS	С	А	А	А	А	А	А	А
MADRIGAL	А	А	А	В	E	А	А	А
INVENTIVA	А	А	А	В	E	А	А	А
COVANCE	А	А	А	В	А	А	А	А
PROSCIENTO	А	А	А	В	А	А	А	А
HISTOINDEX	А	А	А	D	А	А	А	А
PATH AI	А	А	А	В	А	А	А	А

- ^ ongoing research collaboration without directs funds to Dr. Sanyal
- ^^ member of DSMB for a study
- ^^^ provided drug for NIAAA trial of Imm124 for alcoholic hepatitis. I have received no funds from Immuron
- * I am a consultant but have not received personal remuneration
- ** AZ provided remuneration to VCU for my effort as a consultant. This contract was discontinued 1 year ago.
- Research grants represent the site budgets for VCU clinical trials involving these companies and do not support me directly.

Date:	Click or tap to enter a date.		
Your Name:	John Schwarz		
Manuscript Title:	Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: a post hoc analysis of the FALCON 1 trial		
Manuscript Number (if known):	JHEPR-D-22-00117		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
		Time frame: Since the initial planning of the work					
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	☑ None ☑ Image: Second se	Click the tab key to add additional rows.				
3	Royalties or licenses	⊠ None					

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None □ □ □ □ □ □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	Image: None			
		Bristol Myers Squibb	Stock owner		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None			
13	Other financial or non-financial interests	None Bristol Myers Squibb	Full time employee		
Plea	Please place an "X" next to the following statement to indicate your agreement:				
$[\boxtimes]$	I certify that I have	answered every question and have not altered the wo	rding of any of the questions on this form.		